JP2018514564A - 肺送達用のゾルミトリプタン粉末 - Google Patents
肺送達用のゾルミトリプタン粉末 Download PDFInfo
- Publication number
- JP2018514564A JP2018514564A JP2017556853A JP2017556853A JP2018514564A JP 2018514564 A JP2018514564 A JP 2018514564A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2018514564 A JP2018514564 A JP 2018514564A
- Authority
- JP
- Japan
- Prior art keywords
- powder
- zolmitriptan
- powder formulation
- particles
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155910P | 2015-05-01 | 2015-05-01 | |
| US62/155,910 | 2015-05-01 | ||
| PCT/US2016/030219 WO2016179026A1 (en) | 2015-05-01 | 2016-04-29 | Zolmitriptan powders for pulmonary delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514564A true JP2018514564A (ja) | 2018-06-07 |
| JP2018514564A5 JP2018514564A5 (enExample) | 2019-06-06 |
Family
ID=56027187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556853A Pending JP2018514564A (ja) | 2015-05-01 | 2016-04-29 | 肺送達用のゾルミトリプタン粉末 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160317503A1 (enExample) |
| EP (1) | EP3288591A1 (enExample) |
| JP (1) | JP2018514564A (enExample) |
| KR (1) | KR20180002750A (enExample) |
| AU (1) | AU2016257729A1 (enExample) |
| CA (1) | CA2984339A1 (enExample) |
| HK (1) | HK1251998A1 (enExample) |
| MX (1) | MX2017013950A (enExample) |
| WO (1) | WO2016179026A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021535191A (ja) * | 2018-11-13 | 2021-12-16 | シヴィタス セラピューティクス、インコーポレイテッド | 吸入用の呼吸可能なポリヌクレオチド粉末製剤 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1254670A1 (zh) * | 2015-07-02 | 2019-07-26 | Civitas Therapeutics, Inc. | 曲普坦粉末用於肺部给药 |
| JP7419253B2 (ja) * | 2017-12-21 | 2024-01-22 | キウィタス セラピューティクス,インコーポレイテッド | 吸入のための界面活性剤製剤 |
| MX2022014216A (es) | 2020-05-18 | 2022-12-07 | Orexo Ab | Nueva composicion farmaceutica para administracion de farmacos. |
| IL313016A (en) | 2021-11-25 | 2024-07-01 | Orexo Ab | A pharmaceutical preparation that includes adrenaline |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005520843A (ja) * | 2002-03-20 | 2005-07-14 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 呼吸用持続性治療製剤 |
| JP2011510964A (ja) * | 2008-02-01 | 2011-04-07 | ヴェクトゥラ リミテッド | トリプタン類の肺用製剤 |
| JP2013545748A (ja) * | 2010-11-09 | 2013-12-26 | マンカインド コーポレイション | セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| US8496002B2 (en) | 2007-06-12 | 2013-07-30 | Civitas Therapeutics, Inc. | Powder inhaler devices |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
-
2016
- 2016-04-29 AU AU2016257729A patent/AU2016257729A1/en not_active Abandoned
- 2016-04-29 US US15/143,131 patent/US20160317503A1/en not_active Abandoned
- 2016-04-29 CA CA2984339A patent/CA2984339A1/en not_active Abandoned
- 2016-04-29 EP EP16724183.5A patent/EP3288591A1/en not_active Withdrawn
- 2016-04-29 WO PCT/US2016/030219 patent/WO2016179026A1/en not_active Ceased
- 2016-04-29 MX MX2017013950A patent/MX2017013950A/es unknown
- 2016-04-29 JP JP2017556853A patent/JP2018514564A/ja active Pending
- 2016-04-29 HK HK18111327.1A patent/HK1251998A1/zh unknown
- 2016-04-29 KR KR1020177034671A patent/KR20180002750A/ko not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005520843A (ja) * | 2002-03-20 | 2005-07-14 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 呼吸用持続性治療製剤 |
| JP2011510964A (ja) * | 2008-02-01 | 2011-04-07 | ヴェクトゥラ リミテッド | トリプタン類の肺用製剤 |
| JP2013545748A (ja) * | 2010-11-09 | 2013-12-26 | マンカインド コーポレイション | セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021535191A (ja) * | 2018-11-13 | 2021-12-16 | シヴィタス セラピューティクス、インコーポレイテッド | 吸入用の呼吸可能なポリヌクレオチド粉末製剤 |
| JP7632959B2 (ja) | 2018-11-13 | 2025-02-19 | メルツ ファーマスーティカルズ, エルエルシー | 吸入用の呼吸可能なポリヌクレオチド粉末製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017013950A (es) | 2018-08-28 |
| CA2984339A1 (en) | 2016-11-10 |
| WO2016179026A1 (en) | 2016-11-10 |
| AU2016257729A1 (en) | 2017-11-09 |
| KR20180002750A (ko) | 2018-01-08 |
| US20160317503A1 (en) | 2016-11-03 |
| HK1251998A1 (zh) | 2019-05-10 |
| EP3288591A1 (en) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2670987C2 (ru) | Порошки для ингаляции с ультранизкой плотностью | |
| US9155699B2 (en) | Pulmonary delivery for levodopa | |
| JP2018514564A (ja) | 肺送達用のゾルミトリプタン粉末 | |
| JP2018535984A (ja) | リバビリンの医薬組成物 | |
| ES3022184T3 (en) | Rapamycin powders for pulmonary delivery | |
| CN116687887A (zh) | 用于吸入的干粉制剂 | |
| WO2011139253A2 (en) | Pharmaceutical compositions comprising ceftibuten | |
| CN102920678A (zh) | 一种奥氮平固体制剂及其制备方法 | |
| US20240033218A1 (en) | Dihydroergotamine dry powder formulations and methods of use | |
| US10034857B2 (en) | Triptan powders for pulmonary delivery | |
| WO2025157904A1 (en) | Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof | |
| US20060222599A1 (en) | Inhalative powder formulations containing the CGRP-antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine | |
| CA2536050A1 (en) | Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine | |
| HK40023697A (en) | Ultra low density pulmonary powders | |
| WO2011139250A2 (en) | Water dispersible formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190424 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200826 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210105 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210803 |